5.30 PM – 7.30 PM
Thursday, April 28, 2011

Marriott Ballroom, Lobby Level
Washington Marriott Wardman Park
2660 Woodley Road NW
Washington, DC 20008

This educational activity is intended for medical oncologists, radiation oncologists, surgical oncologists, and pathologists actively involved in the management of patients with breast cancer.

Harry Bear, MD, PhD (Chair)
Virginia Commonwealth University
Richmond, Virginia, United States

Michael Dixon, MD
Edinburgh Breast Unit
Western General Hospital
Edinburgh, United Kingdom

Sandra Swain, MD
Washington Hospital Center
Washington, DC, United States

Upon completion of this educational activity, participants should be able to:

• Analyze the role of neoadjuvant therapy in endocrine-responsive breast cancer
• Review current neoadjuvant treatment strategies used in endocrine-responsive breast cancer
• Assess the role of gene expression profiles in selecting optimal neoadjuvant therapy for patients with endocrine-responsive breast cancer

5.30 PM		Welcome and introduction Harry Bear, MD, PhD
5.35 PM		Neoadjuvant therapy of breast cancer: What we know and what we don’t Harry Bear, MD, PhD
5.55 PM		Questions and answers
6.00 PM		Debate Which neoadjuvant treatment strategy is most appropriate for endocrine-responsive breast cancer? Pro Endocrine Therapy: Michael Dixon, MD Pro Chemotherapy: Sandra Swain, MD
6.40 PM		Debate commentary Harry Bear, MD, PhD
6.50 PM		Biologic determinants of systemic therapy in early breast cancer Sandra Swain, MD
7.10 PM		Questions and answers
7.25 PM		Conclusions and take-home messages Harry Bear, MD, PhD
7.30 PM		Adjourn

In accordance with the ACCME Essentials and Standards, everyone involved in planning or presenting this educational activity will be required to disclose any relevant financial relationships with commercial interests in the healthcare industry, and this information will be made available to participants at the start of the activity. In addition, speakers who incorporate information about off-label or investigational use of drugs or devices are required to disclose that information at the beginning of their presentation.

This educational activity may contain discussion of published or and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Sponsors and supporters of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the sponsors and supporters of this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you require reasonable accommodations for a disability in order to participate fully in this continuing education activity, please contact Kimberly Friese at +1 678 892 1364 prior to the live event.